Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
暂无分享,去创建一个
T. Molina | F. Jardin | G. Salles | B. Coiffier | J. Jais | O. Casasnovas | H. Tilly | C. Haioun | G. Laurent | C. Récher | J. Gabarre | F. Morschhauser | C. Fruchart | C. Thieblemont | B. Corront | H. Ghesquières | C. Bonnet | D. Canioni | A. Bosly | M. Janvier | S. Bologna | C. Fermé | Bertrand Coiffi er
[1] L. Staudt,et al. Mechanisms of Disease , 2010 .
[2] B. Coiffier,et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.
[3] K. Morris,et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2011, Cancer.
[4] M. Ziepert,et al. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] Luke A. Gilbert,et al. DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.
[6] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Weiner,et al. Rituximab: mechanism of action. , 2010, Seminars in hematology.
[8] A. Levis,et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study , 2009, Haematologica.
[9] 豊 木村,et al. 胃癌手術におけるCommon Terminology Criteria for Adverse Events v3.0を利用した合併症の評価 , 2009 .
[10] L. Staudt,et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[12] P. Gaulard,et al. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] M. Boccadoro,et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) , 2007, Leukemia.
[14] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[16] D. Weisenburger,et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.
[17] T. Molina,et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.
[18] Dirk Hasenclever,et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. , 2004, Blood.
[19] J Murillo,et al. [B cell lymphoma]. , 2004, Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal.
[20] P. Gaulard,et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. , 2003, Blood.
[21] T. Molina,et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.
[22] T. Molina,et al. Factors predictive of early death in patients receiving high‐dose CHOP (ACVB regimen) for aggressive non‐Hodgkin's lymphoma: a GELA study , 2002, British journal of haematology.
[23] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[24] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[26] B. Coiffier,et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] F. Berger,et al. Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80). , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.